Acceleron Pharma starts Phase 1 ACE-536 trial
ACE-536 is being developed as a treatment of anemia in a global collaboration with Celgene Corporation. The trial aims to evaluate the tolerability, pharmacodynamics, safety and pharmacokinetics of
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The current BAY 94-9343 program is directed against the target molecule mesothelin. BAY 94-9343, a HuCAL-derived antibody-drug conjugate, showed potent, targeted anticancer activity against mesothelin- expressing tumors in